Attorney D

Eyəress Mail Label No.: EV0 Date of Deposit: February 15, 2002

E UNITED STATES PATENT AND TRADEMARK OFFICE

Francois Mach

09/960,471

September 19, 2001

September 19, 2001

Statins (HMG-CoA Reductase Inhibitors) As A Novel Type of Immunomodulator Imunnosuppressor and Anti-Inflammatory Agent IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CATION NO:

For:

No.: 23135-501 CIP (NOV-1\_CHP)

Imunnosuppressor and Anti-Inflammatory Agent

**BOX IDS** 

Commissioner for Patents Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant hereby makes of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, full copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed per se as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

Applicant respectfully requests that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed Form PTO-1449 to evidence that the cited information has been fully considered by the PATENT AND TRADEMARK OFFICE during the examination of this application.

Under 37 C.F.R. § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR 1.17(p) to our Deposit Order Account No. 50-0311 (Reference No. 23135-501 (NOV-1 CIP)).

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Nicholas P. Triano III, Reg. No. 36,397

Attorney for Applicants MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and

POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: February 15, 2002

TRA 1630867v1

Attorney D

No.: 23135-501CIP (N

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PLICANT: Francois Mach

LICATION NO. : 09/960,471 EXAMINER: Not Yet Assigned

§371 FILING DATE:

Express Mail Label: EV05429

Pate of Deposit: February 15, 2002

September 19, 2001

**ART UNIT: 1617** 

FOR: Statins (HMG-CoA Reductase Inhibitors) As A Novel Type of Immunomodulator,

Imunnosuppressor and Anti-Inflammatory Agent

**BOX IDS** 

Commissioner for Patents Washington, D.C. 20231



## TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Information Disclosure Statement (2 pages);
- 2. Modified Form 1449/PTO (2 pages), in duplicate;
- 3. Cited References C1-C20; and
- 4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

No fee is believed to be due. However, if necessary, the Commissioner is authorized to charge any underpayment, or to credit any overpayment, to the undersigned's account. Deposit Account No. 50-0311 Ref. No. 23135-501 CIP. A duplicate copy of this transmittal letter is enclosed herewith.

Wor R. Efrifi, Reg. No. 39,529

Nicholas P. Triano III, Reg. No. 36,397

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and

POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: February 15, 2002

TRA 1630854v1